Literature DB >> 26577382

[The BETER survivorship care initiative for Hodgkin lymphoma; tailored survivorship care for late effects of treatment].

Nicky Dekker1, Mars B van 't Veer, Berthe M P Aleman, Flora E van Leeuwen, John M M Raemaekers.   

Abstract

The Dutch BETER consortium has established a national care infrastructure for Hodgkin lymphoma survivors. 'BETER' [the Dutch word for 'better'] stands for Better care after Hodgkin lymphoma (HL): Evaluation of long-term Treatment Effects and screening Recommendations. The survivorship care focuses on long-term effects of HL treatment. Over 10,000 HL survivors who were treated in the period spanning 1965-2008 have been identified. As part of the survivorship care initiative, specific BETER out-patient clinics have been set up. A dedicated website, www.beternahodgkin.nl, provides HL survivors with relevant information. The stakeholders of the BETER survivorship care programme aim to achieve an improved healthy life expectancy for patients treated for HL.

Entities:  

Mesh：

Year:  2015        PMID： 26577382

Source DB:  PubMed          Journal:  Ned Tijdschr Geneeskd        ISSN： 0028-2162


  8 in total

Review 1.  Long-term risk of second malignancy and cardiovascular disease after Hodgkin lymphoma treatment.

Authors:  Flora E van Leeuwen; Andrea K Ng
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2016-12-02

2.  Long-Term Cause-Specific Mortality in Hodgkin Lymphoma Patients.

Authors:  Simone de Vries; Michael Schaapveld; Cécile P M Janus; Laurien A Daniëls; Eefke J Petersen; Richard W M van der Maazen; Josée M Zijlstra; Max Beijert; Marten R Nijziel; Karijn M S Verschueren; Leontien C M Kremer; Anna M van Eggermond; Pieternella J Lugtenburg; Augustinus D G Krol; Judith M Roesink; Wouter J Plattel; Dick Johan van Spronsen; Gustaaf W van Imhoff; Jan Paul de Boer; Berthe M P Aleman; Flora E van Leeuwen
Journal:  J Natl Cancer Inst       Date:  2021-06-01       Impact factor: 13.506

3.  Colorectal cancer surveillance in Hodgkin lymphoma survivors at increased risk of therapy-related colorectal cancer: study design.

Authors:  Lisanne S Rigter; Manon C W Spaander; Leon M Moons; Tanya M Bisseling; Berthe M P Aleman; Jan Paul de Boer; Pieternella J Lugtenburg; Cecile P M Janus; Eefke J Petersen; Judith M Roesink; John M M Raemaekers; Richard W M van der Maazen; Annemieke Cats; Eveline M A Bleiker; Petur Snaebjornsson; Beatriz Carvalho; Iris Lansdorp-Vogelaar; Katarzyna Jóźwiak; Hein Te Riele; Gerrit A Meijer; Flora E van Leeuwen; Monique E van Leerdam
Journal:  BMC Cancer       Date:  2017-02-07       Impact factor: 4.430

4.  Radiotherapy-Related Dose and Irradiated Volume Effects on Breast Cancer Risk Among Hodgkin Lymphoma Survivors.

Authors:  Sander Roberti; Flora E van Leeuwen; Cécile M Ronckers; Inge M Krul; Florent de Vathaire; Cristina Veres; Ibrahima Diallo; Cécile P M Janus; Berthe M P Aleman; Nicola S Russell; Michael Hauptmann
Journal:  J Natl Cancer Inst       Date:  2022-09-09       Impact factor: 11.816

Review 5.  Cardio-oncology: an overview on outpatient management and future developments.

Authors:  A J Teske; M Linschoten; J A M Kamphuis; W R Naaktgeboren; T Leiner; E van der Wall; J Kuball; A van Rhenen; P A Doevendans; M J Cramer; F W Asselbergs
Journal:  Neth Heart J       Date:  2018-11       Impact factor: 2.380

6.  Light therapy as a treatment of cancer-related fatigue in (non-)Hodgkin lymphoma survivors (SPARKLE trial): study protocol of a multicenter randomized controlled trial.

Authors:  Daniëlle E J Starreveld; Laurien A Daniels; Heiddis B Valdimarsdottir; William H Redd; Jessie L de Geus; Sonia Ancoli-Israel; Susan Lutgendorf; Catharina M Korse; Jacobien M Kieffer; Flora E van Leeuwen; Eveline M A Bleiker
Journal:  BMC Cancer       Date:  2018-09-10       Impact factor: 4.430

7.  Rationale and design of a cohort study on primary ovarian insufficiency in female survivors of Hodgkin's lymphoma: influence on long-term adverse effects (SOPHIA).

Authors:  Inge M Krul; Annemieke W J Opstal-van Winden; Josée M Zijlstra; Yolande Appelman; Sanne B Schagen; Lilian J Meijboom; Erik Serné; Cornelis B Lambalk; Paul Lips; Eline van Dulmen-den Broeder; Michael Hauptmann; Laurien A Daniëls; Berthe M P Aleman; Flora E van Leeuwen
Journal:  BMJ Open       Date:  2018-09-11       Impact factor: 2.692

8.  ONCOR: design of the Dutch cardio-oncology registry.

Authors:  J A M Kamphuis; M Linschoten; M J Cramer; F Alsemgeest; D J W van Kessel; K Urgel; M C Post; O C Manintveld; H C Hassing; C Liesting; A J Wardeh; E G M Olde Bijvank; J Schaap; A M Stevense-den Boer; P A Doevendans; F W Asselbergs; A J Teske
Journal:  Neth Heart J       Date:  2020-11-17       Impact factor: 2.380
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.